Compare Gitlab Inc (GTLB) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs Merck & Co., Inc. — how do they compare? Gitlab Inc trades at $31.58 (market cap $5.54B), while Merck & Co., Inc. trades at $128.07 (market cap $305.29B). The key difference: Merck & Co., Inc. is far larger — about 55.1× Gitlab Inc's market cap, and Merck & Co., Inc. pays a 2.75% dividend while Gitlab Inc pays none. Which is the better fit depends on your goals.
| GTLB | MRK | |
|---|---|---|
Market Cap | $5.54B | $305.29B |
Sector | Technology | Health |
52-Week High | $51.04 | $129.52 |
52-Week Low | $19.42 | $77.60 |
Enterprise Value | $4.29B | $348.71B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) trades at $32.98, down 1.46% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $32.50. The company reported strong revenue growth to $759 million in 2025, though it remains unprofitable with a net margin of -2.49%. Recent news highlights its leadership in DevSecOps and AI-driven software development, including a fourth consecutive Leader recognition in Gartner's Magic Quadrant as of June 2026.
Outlook: GitLab's strategic position in the AI and DevSecOps space offers growth potential, but high valuation multiples and persistent losses pose risks. Investor sentiment is mixed, with analysts divided between buy and hold ratings. Key catalysts include execution on profitability and enterprise adoption of AI tools, while competitive pressures and macroeconomic headwinds remain concerns.
Merck (MRK) trades at $128.00, up 5.96% on the day. The stock shows a bullish technical signal with strong moving average support, while fundamentals reveal robust profitability with a 73.91% gross margin and consistent earnings beats in recent quarters. The company is actively expanding its oncology pipeline through acquisitions, most notably the $6.7 billion tender offer for Terns Pharmaceuticals announced in April 2026.
The outlook is positive, supported by strong analyst consensus (67.57% Buy rating) and a price target implying ~7% upside. Key opportunities include pipeline expansion via M&A and solid cash flow generation. Primary risks involve integration of large acquisitions, patent cliffs for key drugs, and intense competition in the oncology space, which could pressure future growth margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
